1. Home
  2. VNRX vs NEUP Comparison

VNRX vs NEUP Comparison

Compare VNRX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VolitionRX Limited

VNRX

VolitionRX Limited

HOLD

Current Price

$0.16

Market Cap

22.5M

Sector

Health Care

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.66

Market Cap

23.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VNRX
NEUP
Founded
N/A
1996
Country
United States
United States
Employees
N/A
8
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.5M
23.8M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
VNRX
NEUP
Price
$0.16
$4.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$2.00
$21.00
AVG Volume (30 Days)
17.2M
50.2K
Earning Date
05-14-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
38.00
N/A
EPS
N/A
N/A
Revenue
$1,727,384.00
N/A
Revenue This Year
$479.89
N/A
Revenue Next Year
$538.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
40.04
N/A
52 Week Low
$0.15
$3.65
52 Week High
$0.94
$21.31

Technical Indicators

Market Signals
Indicator
VNRX
NEUP
Relative Strength Index (RSI) 34.18 53.16
Support Level N/A $3.91
Resistance Level $0.27 $4.56
Average True Range (ATR) 0.02 0.26
MACD -0.00 0.04
Stochastic Oscillator 6.46 74.47

Price Performance

Historical Comparison
VNRX
NEUP

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: